Go back to the Europarl portal

Choisissez la langue de votre document :

  • bg - български
  • es - español
  • cs - čeština
  • da - dansk
  • de - Deutsch
  • et - eesti keel
  • el - ελληνικά
  • en - English (Selected)
  • fr - français
  • ga - Gaeilge
  • hr - hrvatski
  • it - italiano
  • lv - latviešu valoda
  • lt - lietuvių kalba
  • hu - magyar
  • mt - Malti
  • nl - Nederlands
  • pl - polski
  • pt - português
  • ro - română
  • sk - slovenčina
  • sl - slovenščina
  • fi - suomi
  • sv - svenska
Parliamentary questions
PDF 45kWORD 16k
24 February 2020
Answer given by Ms Kyriakides
on behalf of the European Commission
Question reference: E-004440/2019

1 and 2. Based on Article 241 of the Treaty on the Functioning of the European Union, the Council has requested the Commission(1) to submit a study, by 30 April 2021, regarding the status of novel genomic techniques (NGTs) under Union law in light of the Court of Justice’s judgment on mutagenesis in Case C-528/16(2).

In the study, the Commission intends to provide a state-of-play on the implementation and enforcement of the Genetically Modified Organisms legislation, as regards NGTs, based, inter alia, on contributions from targeted consultations of Member States and stakeholders. These consultations will also provide views on the potential benefits and concerns associated to the use of these techniques.

3. The Council has also requested the Commission to submit a proposal, if appropriate in view of the outcomes of the study, or otherwise to inform the Council on other measures required as a follow-up to the study.

Since the study is at initial stage, the Commission is not in a position to anticipate its outcome and, as a result, cannot prejudge possible measures that might be required as a follow-up to the study.

(1)OJ L 293, 14.11.2019, p. 103‐104
Last updated: 24 February 2020Legal notice - Privacy policy